Institute of Tropical Medicine, Antwerp, Belgium.
Institute of Tropical Medicine, Antwerp, Belgium.
Trends Parasitol. 2017 Mar;33(3):162-174. doi: 10.1016/j.pt.2016.11.003. Epub 2016 Dec 16.
New drugs are needed to control leishmaniasis and efforts are currently on-going to counter the neglect of this disease. We discuss here the utility and the impact of associating drug resistance (DR) studies to drug discovery pipelines. We use as paradigm currently used drugs, antimonials and miltefosine, and complement our reflection by interviewing three experts in the field. We suggest DR studies to be involved at two different stages of drug development: (i) the efficiency of novel compounds should be confirmed on sets of strains including recent clinical isolates with DR; (ii) experimental DR should be generated to promising compounds at an early stage of their development, to further optimize them and monitor clinical trials.
需要新的药物来控制利什曼病，目前正在努力克服人们对这种疾病的忽视。我们在这里讨论了将耐药性（DR）研究与药物发现管道相结合的效用和影响。我们以目前使用的药物，即锑剂和米替福新为例，并通过采访该领域的三位专家来补充我们的思考。我们建议在药物开发的两个不同阶段进行 DR 研究：（i）应在包括具有 DR 的最近临床分离株的菌株集合上确认新型化合物的效率；（ii）应在其开发的早期阶段对有前途的化合物产生实验性 DR，以进一步优化它们并监测临床试验。
